Cover Image
市場調查報告書

慢性腎臟病(慢性腎衰竭):開發中產品分析

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232792
出版日期 內容資訊 英文 197 Pages
訂單完成後即時交付
價格
Back to Top
慢性腎臟病(慢性腎衰竭):開發中產品分析 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 197 Pages
簡介

慢性腎臟病是隨著時間腎功能逐漸喪失的疾病,症狀有噁心、嘔吐、食慾衰退、疲勞感、肌肉無力、睡眠障礙、打嗝、腳·腳踝浮腫等。致病因子有年齡、糖尿病、高血壓、心臟疾病、抽煙、肥胖、高膽固醇值等。

本報告涵括全球慢性腎臟病(慢性腎衰竭)治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

慢性腎臟病(慢性腎衰竭)概要

治療藥的開發

  • 慢性腎臟病(慢性腎衰竭)開發中產品:概要
  • 慢性腎臟病(慢性腎衰竭)開發中產品:比較分析

慢性腎臟病(慢性腎衰竭):開發中的治療藥:各企業

慢性腎臟病(慢性腎衰竭):開發中的治療藥:大學·研究機關別

慢性腎臟病(慢性腎衰竭):開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

慢性腎臟病(慢性腎衰竭):開發中的產品:各企業

慢性腎臟病(慢性腎衰竭):開發中的產品:大學·研究機關別

慢性腎臟病(慢性腎衰竭):治療藥的開發企業

  • Acceleron Pharma, Inc.
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-inRen
  • BioAegis Therapeutics, Inc.
  • Boryung Pharmaceutical Co., Ltd.
  • Complexa, Inc.
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Lupin Limited
  • 日本臟器製藥
  • OPKO Health, Inc.
  • Otsuka Holdings Co., Ltd.
  • Prismic Pharmaceuticals, Inc.
  • Prolong Pharmaceuticals, LLC
  • ProMetic Life Sciences Inc.
  • Reata Pharmaceuticals, Inc.
  • Red Glead Discovery AB
  • RegenMedTX, LLC
  • Resverlogix Corp.
  • Sphaera Pharma Pvt. Ltd.
  • Stelic Institute & Co., Inc.
  • Thrasos Therapeutics Inc.
  • Toray Industries
  • VBS Pharmaceuticals
  • Vicore Pharma AB

慢性腎臟病(慢性腎衰竭):治療藥的評估

  • 單劑治療藥
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (palmidrol + silibinin)
  • ambrisentan
  • ANG-3070
  • ANG-3281
  • ANG-3586
  • ANG-4011
  • apabetalone
  • AS-2444697
  • ASP-6858
  • bardoxolone methyl
  • BR-05001
  • BRN-1889
  • C-21
  • calcium succinate
  • CAR Peptide
  • cardiotoxin
  • Cell Therapy for Chronic Kidney Disease and Type-2 diabetes
  • CXA-10
  • Drug for Kidney Diseases
  • Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology
  • finerenone
  • INT-767
  • IONIS-FXIRx
  • KBP-5074
  • NZ-419
  • obinutuzumab
  • PBI-4050
  • PBI-4419
  • Protein to Activate BMP-7 for Kidney Diseases, Metabolic Disorders and Osteoarthritis
  • Recombinant Plasma Gelsolin Replacement for Renal Disease
  • rivaroxaban
  • Sanguinate
  • 等等

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8538IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9, 15, 19 and 7 respectively for Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively for Chronic Kidney Disease (Chronic Renal Failure).

Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Kidney Disease (Chronic Renal Failure) Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview
    • Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis
  • Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies
  • Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies
  • Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes
  • Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Angion Biomedica Corp.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Bio-inRen
    • BioAegis Therapeutics, Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Cellmid Limited
    • Complexa, Inc.
    • CTI BioPharma Corp.
    • Evotec AG
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • GNI Group Ltd.
    • Intercept Pharmaceuticals, Inc.
    • Lupin Limited
    • Navya Biologicals Pvt Ltd
    • Nippon Zoki Pharmaceutical Co., Ltd.
    • Novartis AG
    • Otsuka Holdings Co., Ltd.
    • Prismic Pharmaceuticals, Inc.
    • Prolong Pharmaceuticals, LLC
    • ProMetic Life Sciences Inc.
    • Reata Pharmaceuticals, Inc.
    • Red Glead Discovery AB
    • RegenMedTX, LLC
    • Resverlogix Corp.
    • Sphaera Pharma Pvt. Ltd.
    • Stelic Institute & Co., Inc.
    • Taisho Pharmaceutical Co., Ltd.
    • Thrasos Therapeutics Inc.
    • Toray Industries, Inc.
    • VBS Pharmaceuticals
    • Vicore Pharma AB
  • Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (palmidrol + silibinin) - Drug Profile
    • ambrisentan - Drug Profile
    • ANG-3070 - Drug Profile
    • ANG-3281 - Drug Profile
    • ANG-3586 - Drug Profile
    • apabetalone - Drug Profile
    • AS-2444697 - Drug Profile
    • bardoxolone methyl - Drug Profile
    • BI-655088 - Drug Profile
    • BLR-400 - Drug Profile
    • BMS-986177 - Drug Profile
    • BRN-1889 - Drug Profile
    • C-21 - Drug Profile
    • CAB-101 - Drug Profile
    • calcium succinate - Drug Profile
    • CAR Peptide - Drug Profile
    • cardiotoxin - Drug Profile
    • Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile
    • CXA-10 - Drug Profile
    • dapagliflozin propanediol - Drug Profile
    • Drug for Kidney Diseases - Drug Profile
    • F-351 - Drug Profile
    • finerenone - Drug Profile
    • INT-767 - Drug Profile
    • KBP-5074 - Drug Profile
    • LHW-090 - Drug Profile
    • NAV-003 - Drug Profile
    • NZ-419 - Drug Profile
    • obinutuzumab - Drug Profile
    • pacritinib - Drug Profile
    • PBI-4050 - Drug Profile
    • PBI-4419 - Drug Profile
    • Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
    • Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile
    • Sanguinate - Drug Profile
    • Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile
    • Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease and Hypertension - Drug Profile
    • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile
    • Small Molecules for Chronic Kidney Disease - Drug Profile
    • Small Molecules for Chronic Kidney Disease - Drug Profile
    • Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile
    • sotatercept - Drug Profile
    • SP-20103 - Drug Profile
    • SPR-494 - Drug Profile
    • STNM-310 - Drug Profile
    • Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
    • Synthetic Peptides for Chronic Kidney Disease - Drug Profile
    • TNT-009 - Drug Profile
    • tolvaptan - Drug Profile
    • torsemide ER - Drug Profile
    • TRC-101 - Drug Profile
    • TS-143 - Drug Profile
    • Vida-5 - Drug Profile
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
  • Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
  • Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2016
  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Acceleron Pharma, Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bio-inRen, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics, Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Limited, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa, Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CTI BioPharma Corp., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences, Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Limited, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Navya Biologicals Pvt Ltd, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Red Glead Discovery AB, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by RegenMedTX, LLC, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Stelic Institute & Co., Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Thrasos Therapeutics Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries, Inc., H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VBS Pharmaceuticals, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects (Contd..1), H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects (Contd..2), H2 2016
  • Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2016
  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top